Journal
PHARMACOLOGY & THERAPEUTICS
Volume 182, Issue -, Pages 152-160Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2017.08.012
Keywords
Bevacizumab; Hypertension; VEGF; Pharmacogenetics
Categories
Funding
- Genentech through the Alliance Clinical Trial Foundation
- Pharmacogenomics Development Fund [P30CA082103]
- NIH [T32GM007175, F31GM113350]
Ask authors/readers for more resources
Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment are not well understood. In this review, we outline research efforts to understand the mechanisms and pathophysiology of hypertension resulting from bevacizumab treatment. Moreover, we highlight current knowledge of the pharmacogenetics of bevacizumab-induced hypertension, which may be used to develop strategies to prevent or minimize this toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available